Pure Global

Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis - Trial NCT06058546

Access comprehensive clinical trial information for NCT06058546 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tasly Pharmaceutical Group Co., Ltd and is currently Not yet recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 180 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06058546
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06058546
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial of Efficacy and Safety of Jiuweihuaban Pill in the Treatment of Moderate to Severe Plaque Psoriasis(Syndrome of Blood-heat ).

Study Focus

Plaque Psoriasis

Jiuweihuaban Pill placebo

Interventional

drug

Sponsor & Location

Tasly Pharmaceutical Group Co., Ltd

Beijing,Changchun,Changsha,Chengdu,Jinan,Kunming,Nanyang,Shenyang,Tianjin,Wenzhou,Xiamen,Xingtai, China

Timeline & Enrollment

Phase 2

Oct 01, 2023

Oct 01, 2025

180 participants

Primary Outcome

PASI 75

Summary

This study will evaluate the efficacy and safety of Jiuweihuaban Pill in the treatment of
 moderate to severe plaque psoriasis(syndrome of blood-heat ).

ICD-10 Classifications

Psoriasis
Large plaque parapsoriasis
Other psoriasis
Small plaque parapsoriasis
Arthropathic psoriasis

Data Source

ClinicalTrials.gov

NCT06058546

Non-Device Trial